We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 31,074 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/2/2018 13:36 | We all know for definite that news is coming, on more than one front. If Carlsberg did N4P news .... | jakleeds | |
23/2/2018 13:24 | 13:16:59 31.0000 4,858 O 31.0000 32.0000 Sell 757,690 495,787 13:15:32 31.0000 4,858 O 31.0000 32.0000 Sell 757,690 490,929 13:14:24 31.0000 4,858 O 31.0000 32.0000 Sell 757,690 486,071 13:13:01 31.0000 4,858 O 31.0000 32.0000 Sell 757,690 481,213 Why would the MM`s be trying to suppress the SP? They probably know that news is coming and don`t want to be left without stock. | hughwilson | |
23/2/2018 12:16 | Urigem, That is what I said before. 1286 cancer products in 2016. All would benefit from the improved delivery system that Nuvec offers, and the 1286 is just for cancer treatments. | hughwilson | |
23/2/2018 12:13 | Today is N4P`s last day in Japan. I don`t envisage Nigel coming away empty-handed so we are looking probably at a number of news releases over the next few minutes/days/weeks. | hughwilson | |
23/2/2018 11:57 | Just look at that one year chart... | parob | |
23/2/2018 11:53 | if you want to buy any in quantity you either have to wait for some sellers or send to the broker? | jimmmy | |
23/2/2018 11:49 | Have to go to market now for an even small amount. Bring it on! | garbut | |
23/2/2018 11:48 | new high today it would seem...DYOR | qs99 | |
23/2/2018 11:09 | Updown up down up.. A quick shot of reformulated Viagra would cure today's chart | urigem | |
23/2/2018 10:52 | A bit of a shake and back up we go. Huge appetite for these shares. MC still only £28 million. | parob | |
23/2/2018 09:06 | Turbulent times for the consolidation of this share. But no matter how much the mms knock, it continues to bounce back strong. Roll on 40p:))) | ch1rp | |
23/2/2018 08:36 | I would like a nice Friday afternoon RNS- would make my weekend | urigem | |
23/2/2018 08:23 | Very happy at these levels, I think if viagra plasma results come back as expected, NT will be tempted to go for Phase 111 alone. Once the Mkt grab a inspiration on the numbers may well be the best way to go.. Especially if some deals with Nuvec allow it to pay for it | urigem | |
23/2/2018 07:50 | Given such a strong finish right into the close yesterday I suspect we will see a mad scramble for these today. 10 and a half minutes left ... | jakleeds | |
23/2/2018 07:28 | And the first collaborative project is in the bag with AZ. Who's next!? | parob | |
23/2/2018 07:15 | FROM N4P Website N4 Pharma is investigating the use of its Nuvec technology in the field of cancer vaccines. Global revenues for the cancer vaccines market are forecast by Global Business Intelligence in their November report “Global Cancer Vaccines Market to 2022” to grow at a CAGR of 16.9 per cent., from $2.5 billion in 2015 to $7.5 billion in 2022. The cancer vaccine pipeline is large with 1,286 products in development in November 2016. This represents a significant market opportunity for Nuvec. The N4 Pharma Directors believe that once the ‘proof of concept’ data pack has been developed for Nuvec, which is expected to be completed within the next 12 months, business development will commence to establish collaborative research projects with potential partners. | urigem | |
22/2/2018 21:19 | Hugh Wilson@HughWilson232 | parob | |
22/2/2018 20:00 | Thats not a service i personally will offer, any volunteers for the “ dont be out of this share at the weekend ” service? Hee hee hee!!! | escapetohome | |
22/2/2018 19:51 | its about time someone said 'not one to be out of over the weekend' | paddyfool | |
22/2/2018 19:16 | escapetohome22 Feb '18 - 08:18 - 81 of 81 Edit 0 0 0 BLUE FINISH , strong recovery as per usual! Oops! my blue finish advice service was on the other thread this am . Sorry folks ,!! | escapetohome | |
22/2/2018 18:49 | Aim_Chaos on twitter just now:#N4P's Nuvec platform already attracting the likes of AstraZeneca - amazing. Many more tier 1 pharmas will partner with N4 for Nuvec in future, IMO. A genuine industry gamechanger.Sildenaf | parob | |
22/2/2018 18:34 | tp6, It does look likely that we will get news on JV`s or collaborations from Japan in the coming days/weeks. | hughwilson | |
22/2/2018 18:21 | Japan, one of the world's richest business markets, once had a reputation as a difficult business environment for some foreign companies. So why have many of the world's best-known life science companies successfully expanded into Japan in recent years?From Finland to Israel, from Australia to Portugal, from the U.S. to the U.K, small and large corporations have realized that Japan's aging society represents opportunities in health sciences, while the country has loosened several key policies, regulations, and laws to open the door for foreign investment. | tp6 | |
22/2/2018 18:21 | Parob, N4`s final day in Japan is the 24th. After that we have 3 months of the British Embassy facilitating any negotiations. | hughwilson | |
22/2/2018 18:20 | https://hbr.org/spon | tp6 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions